Currently out of the existing stock ratings of Derek Archila, 268 are a BUY (68.54%), 112 are a HOLD (28.64%), 11 are a SELL (2.81%).

Derek Archila

Work Performance Price Targets & Ratings Chart

Analyst Derek Archila, currently employed at WELLS FARGO, carries an average stock price target met ratio of 51.96% that have a potential upside of 48.88% achieved within 195 days.

Derek Archila’s has documented 741 price targets and ratings displayed on 65 stocks. The coverage is on Healthcare, Energy, Technology, Financial Services sectors.

Most recent stock forecast was given on ALMS, Alumis Common Stock at 02-Sep-2026.

Wall Street Analyst Derek Archila

Analyst best performing recommendations are on EQ (EQUILLIUM).
The best stock recommendation documented was for EQ (EQUILLIUM) at 7/10/2020. The price target of $10 was fulfilled within 3 days with a profit of $6.81 (213.48%) receiving and performance score of 711.6.

Average potential price target upside

of $108.8 (79.69%) on DBVT (DBV TECHNOLOGIES).
of $74.57 (20.74%) on ARGX (ARGENX NV ADR).
of $67.63 (60.23%) on ASND (ASCENDIS PHARMA AS).

AIMT Aimmune Therapeutics AMRN Amarin PLC ASND Ascendis Pharma AS CBAY Cymabay Therapeu IMVT Immunovant KZR Kezar Life Sciences MNTA Momenta Pharmaceuticals PCRX Pacira Pharmaceuticals RYTM Rhythm Pharmaceuticals SGYP Synergy Pharmaceuticals VNDA Vanda Pharmaceuticals GLPG Galapagos NV ADR ICPT Intercept Pharmaceuticals NGM NGM Biopharmaceuticals PHAS PhaseBio Pharmaceuticals PRNB Principia Biopharma APLS Apellis Pharmaceuticals ARVN Arvinas CCCC C4 Therapeutics HZNP Horizon Pharma PLC INCY yte KYMR Kymera Therapeutics NRIX Nurix Therapeutics CABA Cabaletta Bio GLUE Monte Rosa Therapeutics MORF Morphic ARGX argenx NV ADR RXDX Prometheus Biosciences URGN UroGen Pharma Ltd ARNA Arena Pharmaceuticals BPMC Blueprint Medicines Corp ESPR Esperion Therapeutics HRTX Heron Therapeuti TEVA Teva Pharma Industries Ltd ADR ZYNE Zynerba Pharmaceuticals CLDX Celldex Therapeutics DICE Dice Molecules Holdings LLC MOR MorphoSys AG ADR VTYX Ventyx Biosciences ZNTL Zentalis Pharmaceuticals Llc ANAB AnaptysBio ANNX Annexon EXEL Exelixis VRDN Viridian Therapeutics ZYME Zymeworks Common Stock SLRN ACELYRIN, INC. Common Stock CQP Cheniere Energy Partners LP EQ Equillium STRO Sutro Biopharma ALNY Alnylam Pharmaceuticals BBIO BridgeBio Pharma ORIC Oric Pharmaceuticals PRGO Perrigo Company PLC SLNO Soleno Therapeutics AI C3 Ai ALMS Alumis Common Stock ALXN Alexion Pharmaceuticals BP BP PLC ADR CB Chubb Ltd DBVT DBV Technologies IRON Disc Medicine IVA Inventiva Sa KYTX Kyverna Therapeutics, Common Stock LUMO Lumos Pharma SEPN Septerna, Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Derek Archila (WELLS FARGO)

Hold Since 19-Dec-2019

$18

6 years 9 days ago
(01-Sep-2020)

3/3 (100%)

$3.19 (21.54%)

Charles Duncan (CANTOR FITZGERALD)

Buy Since 17-Nov-2015

$35

$0.51 (1.48%)

6 years 10 days ago
(31-Aug-2020)

5/14 (35.71%)

$0.78 (2.28%)

488

Evan Seigerman (BMO)

Hold Since 04-Feb-2020

$34.5

$0.01 (0.03%)

6 years 10 days ago
(31-Aug-2020)

5/5 (100%)

$0.28 (0.82%)

138

Liana Moussatos

Buy Since 14-Jun-2016

$34.5

$0.01 (0.03%)

$66

6 years 10 days ago
(31-Aug-2020)

1/9 (11.11%)

$0.28 (0.82%)

Christopher Raymond (RAYMOND JAMES)

Buy Since 03-Jun-2019

$60

6 years 10 days ago
(31-Aug-2020)

0/19 (0%)

$41.31 (221.03%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Derek Archila most bullish on?

Potential upside of $407.93 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Derek Archila most reserved on?

Potential downside of -$10.11 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

What Year was the first public recommendation made by Derek Archila?

On 2016